Dr. Timothy Wassenaar, MD
Claim this profileUW Cancer Center at ProHealth Care
Expert in Skin Cancer
Expert in Lung Cancer
116 reported clinical trials
193 drugs studied
About Timothy Wassenaar, MD
Education:
- Received an MD from the University of Wisconsin School of Medicine and Public Health in 2015.
Experience:
- Completed a Residency in Radiation Oncology at the University of Wisconsin Hospital and Clinics in 2020.
- Undertook a Fellowship in Stereotactic Body Radiotherapy (SBRT) and Stereotactic Radiosurgery (SRS) at the same institution in 2021.
- Currently affiliated with the UW Cancer Center at ProHealth Care.
Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Timothy Wassenaar, MD is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
More about Timothy Wassenaar, MD
Clinical Trial Related6 years of experience running clinical trials · Led 116 trials as a Principal Investigator · 56 Active Clinical TrialsTreatments Timothy Wassenaar, MD has experience with
- Nivolumab
- Pembrolizumab
- Carboplatin
- Paclitaxel
- Atezolizumab
- Fluorouracil
Breakdown of trials Timothy Wassenaar, MD has run
Skin Cancer
Lung Cancer
Stomach Cancer
Relapse
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Timothy Wassenaar, MD specialize in?
Timothy Wassenaar, MD focuses on Skin Cancer and Lung Cancer. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is Timothy Wassenaar, MD currently recruiting for clinical trials?
Yes, Timothy Wassenaar, MD is currently recruiting for 55 clinical trials in Waukesha Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Timothy Wassenaar, MD has studied deeply?
Yes, Timothy Wassenaar, MD has studied treatments such as Nivolumab, Pembrolizumab, Carboplatin.
What is the best way to schedule an appointment with Timothy Wassenaar, MD?
Apply for one of the trials that Timothy Wassenaar, MD is conducting.
What is the office address of Timothy Wassenaar, MD?
The office of Timothy Wassenaar, MD is located at: UW Cancer Center at ProHealth Care, Waukesha, Wisconsin 53188 United States. This is the address for their practice at the UW Cancer Center at ProHealth Care.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.